Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study - Wikidata - wikimedia - TriplyDB

Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study

Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study

http://www.wikidata.org/entity/Q34235130

about

Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma.Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.

P2860

Q35628530-15D9D9BB-8E62-4861-B4C2-E0735C043E70 Q35712214-6EE20F73-5366-4C0A-8604-0B7B43A66F53 Q36404083-BCD6314D-7F34-45BA-A3B7-0AF46C434FFD Q39106800-1C4FFE48-E0E0-49F5-86F5-E96E642A7CA1

P2860

Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study

http://www.wikidata.org/entity/Q34235130

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Performance of standard proced ...... a large Caucasian cohort study

@ast

Performance of standard proced ...... a large Caucasian cohort study

@en

Performance of standard proced ...... a large Caucasian cohort study

@nl

type

label

Performance of standard proced ...... a large Caucasian cohort study

@ast

Performance of standard proced ...... a large Caucasian cohort study

@en

Performance of standard proced ...... a large Caucasian cohort study

@nl

prefLabel

Performance of standard proced ...... a large Caucasian cohort study

@ast

Performance of standard proced ...... a large Caucasian cohort study

@en

Performance of standard proced ...... a large Caucasian cohort study

@nl

P1433

Q34235130-74383BC7-6A84-4005-AA30-70B780BE2582

P1476

Q34235130-1E658ADC-E015-4877-82B4-2D23C80E7EF3

P2093

Q34235130-0D9AE6CA-4343-47DA-A333-A25F6EEFD22C

Q34235130-141B211B-8F68-4530-8B7E-C3DC8203D894

Q34235130-1BD2106B-D25D-44BC-A184-31FD715E993E

Q34235130-520913D1-2F13-448C-870B-DC912D96A304

Q34235130-6D3F643F-17E9-4D39-BAAD-2076D7A50E9C

Q34235130-77BF51D8-AAA6-452B-AB23-B3A532A9443E

Q34235130-903EC149-7663-47FE-89C8-508B66FF1E29

Q34235130-B46DE366-BB26-4F2E-AD85-EAB440E35D02

Q34235130-FAEBE463-DFCB-46A1-A5FE-7B48C29B03D8

P2860

Q34235130-1CB6CB34-F02B-4A39-80E0-38CF19E3D2AE

Q34235130-1E79B8C3-A295-4402-9AB7-E9B4A6E97F24

Q34235130-24594205-04FF-4019-B930-FC96DCEBC06F

Q34235130-2E3B7F87-2CC1-427C-9437-8C98B913631E

Q34235130-43E8AB8E-561A-4819-A3F6-CD5A2755482B

Q34235130-5D1992D0-E16E-49DC-B1D4-2A22242E24C4

Q34235130-68FB3060-F65C-4D57-AE7B-1A3D7CC6A9C5

Q34235130-6E475D90-3C07-4AE3-A843-70670D892127

Q34235130-74822CA2-946D-44F6-8201-C07C61C30989

Q34235130-7ED96C10-4E51-42FC-8A78-AF878490F429

P2888

Q34235130-D7CDE7AF-4915-4298-B248-9BB133EC9610

P304

Q34235130-46E5694C-DE72-48A7-B335-418EE425D085

P31

Q34235130-A8B5F9C4-C700-4068-8354-C9564E5DAF2F

P356

Q34235130-78EBD984-CB90-4DF4-BB22-BCC4CB879D25

P433

Q34235130-2CFD9BD3-A88F-47CB-8DC2-4D117D28E204

P478

Q34235130-CDE64F05-8DF7-4B6E-AEEF-46B6518835ED

P50

Q34235130-B3AD7679-D10D-4624-8226-32ACE3997B97

P577

Q34235130-D8C89A2D-8294-44F9-AB84-9E9FD0094F02

P5875

Q34235130-22C0D01C-819F-4D4B-B1DD-4B02DB2840EE

P6179

Q34235130-B64D4A39-B067-4A2F-B179-9DC53A4A4D9D

P698

Q34235130-160B146D-669B-43D4-9F55-38ECC9A5DB24

P932

Q34235130-2E589F3E-B197-448B-98D5-A15C89DC5069

P356

S40247-014-0009-0

P1433

Translational respiratory medicine

P1476

Performance of standard proced ...... a large Caucasian cohort study

@en

P2093

Christophe Dooms

http://www.w3.org/2001/XMLSchema#string

Eric Verbeken

http://www.w3.org/2001/XMLSchema#string

Inge Hantson

http://www.w3.org/2001/XMLSchema#string

Isabelle Wauters

http://www.w3.org/2001/XMLSchema#string

Johan Vansteenkiste

http://www.w3.org/2001/XMLSchema#string

Kris Nackaerts

http://www.w3.org/2001/XMLSchema#string

Liesbet Vliegen

http://www.w3.org/2001/XMLSchema#string

Peter Vandenberghe

http://www.w3.org/2001/XMLSchema#string

Sara Vander Borght

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

Screening for epidermal growth factor receptor mutations in lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.

P2888

s40247-014-0009-0

P304

9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40247-014-0009-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266380169

http://www.w3.org/2001/XMLSchema#string

P6179

1043605365

http://www.w3.org/2001/XMLSchema#string

P698

25264519

http://www.w3.org/2001/XMLSchema#string

P932

4173071

http://www.w3.org/2001/XMLSchema#string